Specialty Pharmacy

Top news of the day from across the health care landscape.

Report demonstrates an increase in generic and new drug approvals, Orphan Drug designations, and an increase in the use of expediated approval programs.

Two large studies demonstrating patient-reported outcomes showed that quality of life was maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer (CRC) and unresectable hepatocellular carcinoma (HCC). The results were presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California, from January 23-25.

A blood-based screening test using cell-free DNA may be able to identify cancer at earlier stages than what was previously possible, according to research to be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Tazemetostat blocks any activity of the EZH2 methyltransferase, which may help keep the cancer cells from further growth.

Pharmacies are using technology not only to offer safe filling, but generate greater engagement with their customer base.

Pfizer will become the first to launch 3 oncology monoclonal antibody biosimilar treatments to the US market.

Top news of the day from across the health care landscape.

A proposed FDA guidance could significantly impact veterinary practices and their ability to compound medicines for animal patients, according to a national survey.1

Biosimilars, which at the most simplistic level can be thought of as a type of generic option for a biologic, offer an opportunity to help reduce total biologic drug spend.

Valoctocogene roxaparvovec (Valrox, BioMarin Pharmaceutical Inc) would be the first gene therapy in the United States for the most common form of hemophilia if approved by the FDA.1

The shift from fee-for-service to a value-based care payment model represents the growing understanding of the value of health care providers in improving overall patient outcomes.

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

Top news of the day from across the health care landscape.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.

Top news of the day from across the health care landscape.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The report projects changes in upcoming health care markets, including kidney care, digital health, drug cost transparency, the loneliness epidemic, and the self-care market.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Safety net providers, which historically work in underserved communities, have successfully petitioned state legislatures to take action on 340B 2-tier pricing.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.

Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.